Stay updated on Antibody Drug Conjugate in Advanced Breast Cancer HER2 Clinical Trial
Sign up to get notified when there's something new on the Antibody Drug Conjugate in Advanced Breast Cancer HER2 Clinical Trial page.

Latest updates to the Antibody Drug Conjugate in Advanced Breast Cancer HER2 Clinical Trial page
- ChecktodayChange DetectedThe site revision label changed from v3.8.0 to v3.8.1, with the clinical trial record otherwise unchanged.SummaryDifference0.1%

- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe record for the XMT-1522 Phase 1b study of patients with advanced HER2-expressing cancers is displayed, including participant criteria, study locations, treatment plan, outcome measures, and record dates.SummaryDifference40%

- Check21 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check28 days agoChange DetectedA site-wide notice says NIH websites are transitioning terminology from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check35 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.1 to v3.7.2. The page continues to display a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check42 days agoChange DetectedThe site revision marker changed from v3.7.0 to v3.7.1 while the page continued to display a 403 error.SummaryDifference0.2%

Stay in the know with updates to Antibody Drug Conjugate in Advanced Breast Cancer HER2 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Antibody Drug Conjugate in Advanced Breast Cancer HER2 Clinical Trial page.